The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables

Journal of Molecular Histology

Volumn 45, Issue 6, 2014, Pages 679-687

  Turan, Gulay ^a   Usta, Ceyda Sancakli ^b   Usta, Akin ^c   Kanter, Mehmet ^b   Tavli, Lema ^a   Karacan, Meric ^d   Celik, Cetin ^a   Eser, Metin ^b  

^a SELCUK UNIVERSITY   (Turkey)

^b ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

^c Fatih Sultan Mehmet Education and Training Hospital   (Turkey)

^d ISTANBUL YENI YUZYIL UNIVERSITY   (Turkey)

Author keywords

Cycline D1; HER 2 neu (c erbB2); Immunohistochemistry; Serous ovarian neoplasms; Surviving

Indexed keywords

BIRC5 PROTEIN, HUMAN; CCND1 PROTEIN, HUMAN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

ADOLESCENT; ADULT; AGED; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYCLIN D1; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MIDDLE AGED; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; YOUNG ADULT;

EID: 84937199025     PISSN: 15672379     EISSN: 15672387     Source Type: Journal    
DOI: 10.1007/s10735-014-9591-2     Document Type: Article

References (46)

1. Alao JP (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6:24
2. Altieri DC (2006) The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 18(6):609–615
3. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3(8):917–921
4. Barbieri F, Lorenzi P, Ragni N, Schettini G, Bruzzo C, Pedullà F et al (2004) Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer. Oncology 66(4):310–315
5. Biliran H Jr, Wang Y, Banerjee S, Xu H, Heng H, Thakur A et al (2005) Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res Off J Am Assoc Cancer Res 11(16):6075–6086
6. Chen L, Liang L, Yan X, Liu N, Gong L, Pan S et al (2013) Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 23(2):256–263
7. Cui X, Liu Y, Wan C, Lu C, Cai J, He S, Ni T, Zhu J, Wei L, Zhang Y, Qian H (2014) Decreased expression of SERPINB1 correlates with tum or invasion and poor prognosis in hepatocellular carcinoma. J Mol Histol 45(1):59–68
8. Felisiak-Golabek A, Rembiszewska A, Rzepecka IK, Szafron L, Madry R, Murawska M et al (2011) Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients. J Ovarian Res 4(1):20
9. Ferrandina G, Legge F, Martinelli E, Ranelletti FO, Zannoni GF, Lauriola L et al (2005) Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer 92(2):271–277
10. FIGO (International Federation of Gynecology and Obstetrics) (2006) 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S1–S257
11. Goff BA, Mandel L, Muntz HG, Melancon CH (2000) Ovarian carcinoma diagnosis. Cancer 89(10):2068–2075
12. Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Yeap BY, Sugarbaker DJ et al (2007) Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. J Pathol 211(4):439–446
13. Grushko TA, Filiaci VL, Mundt AJ, Ridderstråle K, Olopade OI, Fleming GF et al (2008) An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 108(1):3–9
14. Gul AE, Keser SH, Barisik NO, Kandemir NO, Cakir C, Sensu S et al (2010) The relationship of c-erbB2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas. Diagn Pathol 5:13
15. Heublein S, Vrekoussis T, Mayr D, Friese K, Lenhard M, Jeschke U et al (2013) Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR). J Ovarian Res 6(1):6
16. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ (1993) Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7(3):331–342
17. Kohlberger P, Loesch A, Koelbl H, Breitenecker G, Kainz C, Gitsch G (1996) Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer. Cancer Lett 98(2):151–155
18. Konno R, Yamakawa H, Utsunomiya H, Ito K, Sato S, Yajima A (2000) Expression of survivin and Bcl-2 in the normal human endometrium. Mol Hum Reprod 6(6):529–534
19. Kucukgoz Gulec U, Gumurdulu D, Guzel AB, Paydas S, Seydaoglu G, Acikalin A et al (2014) Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma. Arch Gynecol Obstet 289(2):393–398
20. Lanitis E, Dangaj D, Hagemann IS, Song D-G, Best A, Sandaltzopoulos R et al (2012) Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS One 7(11):e49829
21. Li F, Ling X (2006) Survivin study: an update of « what is the next wave » ? J Cell Physiol 208(3):476–486
22. Li W, Jiang H-R, Xu X-L, Wang J, Zhang J, Liu M-L et al (2010) Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo. Int J Mol Sci 11(10):3999–4013
23. Lin C-K, Chao T-K, Yu C-P, Yu M-H, Jin J-S (2009) The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS Acta Pathol Microbiol Immunol Scand 117(3):162–175
24. Liu Z, Wu X, Zhang F, Han L, Bao G, He X, Xu Z (2013) AhR expression is increased in hepatocellular carcinoma. J Mol Histol 44(4):455–461
25. Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA (2006) EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol 100(1):101–106
26. Nossov V, Amneus M, Su F, Lang J, Janco JMT, Reddy ST et al (2008) The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 199(3):215–223
27. Nowee ME, Dorsman JC, Piek JMJ, Kosma VM, Hämäläinen K, Verheijen RHM et al (2007) HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study. Histopathology 51(5):666–673
28. Odicino FE, Bignotti E, Rossi E, Pasinetti B, Tassi RA, Donzelli C et al (2008) HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 18(1):14–21
29. Qian X, Xi X, Li L (2011) Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma. Appl Immunohistochem Mol Morphol AIMM Off Publ Soc Appl Immunohistochem 19(2):126–132
30. Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S (2008) Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet 102(2):128–131
31. Serrano-Olvera A, Dueñas-González A, Gallardo-Rincón D, Candelaria M, De la Garza-Salazar J (2006) Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 2(3):180–190
32. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M (2002) Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 21(2):315–320
33. Sylvia MT, Kumar S, Dasari P (2012) The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables. Indian J Pathol Microbiol 55(1):33–37
34. Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I (2002) Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma. Int J Mol Med 10(2):211–216
35. Ueda M, Yamashita Y, Takehara M, Terai Y, Kumagai K, Ueki K (2002) Survivin gene expression in endometriosis. J Clin Endocrinol Metab 87(7):3452–3459
36. Uharcek P (2008) Prognostic factors in endometrial carcinoma. J Obstet Gynaecol Res 34(5):776–783
37. Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D (2006) HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer Off J Int Gynecol Cancer 16(5):1897–1902
38. Wheatley SP, McNeish IA (2005) Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 247:35–88
39. Worsley SD, Ponder BA, Davies BR (1997) Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol 64(2):189–195
40. Wu G-Q, Xie D, Yang G-F, Liao Y-J, Mai S-J, Deng H-X et al (2009) Cell cycle-related kinase supports ovarian carcinoma cell proliferation via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma. Int J Cancer J Int Cancer 125(11):2631–2642
41. Wu Y-Y, Chen L, Wang G-L, Zhang Y-X, Zhou J-M, He S, Qin J, Zhu Y-Y (2013) Inhibition of hepatocellular carcinoma growth and angiogenesis by dual silencing of NET-1 and VEGF. J Mol Histol 44(4):433–445
42. Yamamoto H, Ngan CY, Monden M (2008) Cancer cells survive with survivin. Cancer Sci 99(9):1709–1714
43. Yamashita S-I, Masuda Y, Kurizaki T, Haga Y, Murayama T, Ikei S et al (2007) Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res 27(4C):2803–2808
44. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L et al (2002) Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci CMLS 59(8):1406–1412
45. Zaidi SK, Grandy RA, Lopez-Camacho C, Montecino M, van Wijnen AJ, Lian JB et al (2014) Bookmarking target genes in mitosis: a shared epigenetic trait of phenotypic transcription factors and oncogenes? Cancer Res 74(2):420–425
46. Zhang M, Coen JJ, Suzuki Y, Siedow MR, Niemierko A, Khor L-Y et al (2010) Survivin is a potential mediator of prostate cancer metastasis. Int J Radiat Oncol Biol Phys 78(4):1095–1103